CN108368127B - 化合物及其作为ep4受体拮抗剂的用途 - Google Patents

化合物及其作为ep4受体拮抗剂的用途 Download PDF

Info

Publication number
CN108368127B
CN108368127B CN201680042838.4A CN201680042838A CN108368127B CN 108368127 B CN108368127 B CN 108368127B CN 201680042838 A CN201680042838 A CN 201680042838A CN 108368127 B CN108368127 B CN 108368127B
Authority
CN
China
Prior art keywords
group
compound
methyl
alkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680042838.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN108368127A (zh
Inventor
D·巴拉卡尔
A·M·德什潘德
S·帕蒂尔
Y·瓦曼
A·帕曼德
D·贾达夫
B·库尔卡尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN108368127A publication Critical patent/CN108368127A/zh
Application granted granted Critical
Publication of CN108368127B publication Critical patent/CN108368127B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201680042838.4A 2015-07-23 2016-07-22 化合物及其作为ep4受体拮抗剂的用途 Expired - Fee Related CN108368127B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2244/DEL/2015 2015-07-23
IN2244DE2015 2015-07-23
PCT/JP2016/072244 WO2017014323A1 (en) 2015-07-23 2016-07-22 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists

Publications (2)

Publication Number Publication Date
CN108368127A CN108368127A (zh) 2018-08-03
CN108368127B true CN108368127B (zh) 2020-12-11

Family

ID=56740432

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680042838.4A Expired - Fee Related CN108368127B (zh) 2015-07-23 2016-07-22 化合物及其作为ep4受体拮抗剂的用途

Country Status (7)

Country Link
US (2) US10745397B2 (enExample)
EP (1) EP3325490B1 (enExample)
JP (1) JP6689297B2 (enExample)
CN (1) CN108368127B (enExample)
CA (1) CA2993312A1 (enExample)
DK (1) DK3325490T3 (enExample)
WO (1) WO2017014323A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
TW201900180A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
HRP20211380T1 (hr) 2017-05-18 2021-11-26 Idorsia Pharmaceuticals Ltd Derivati pirimidina kao modulatori receptora pge2
AR111807A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
SI3625224T1 (sl) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd N-substituirani indolni derivati
US20200352912A1 (en) * 2018-01-26 2020-11-12 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Antimicrobial compositions and methods of using the same
US20200352906A1 (en) * 2018-02-05 2020-11-12 Shenzhen Ionova Life Science Co., Ltd. Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases
CA3114551A1 (en) 2018-10-23 2020-04-30 Basf Se Tricyclic pesticidal compounds
AU2020232616A1 (en) * 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
CN112094249B (zh) * 2019-06-17 2022-03-08 中国科学院苏州纳米技术与纳米仿生研究所 磺胺甲噻二唑-糖精共晶及其制备方法与应用
EP4620531A3 (en) 2019-11-08 2025-11-26 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2021209265A1 (en) 2020-04-14 2021-10-21 Basf Se Tricyclic pesticidal compounds
EP3907214A1 (en) * 2020-05-04 2021-11-10 Dompe' Farmaceutici S.P.A. Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use
TW202228674A (zh) 2020-11-13 2022-08-01 日商小野藥品工業股份有限公司 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0752421A1 (en) * 1995-07-07 1997-01-08 Zeneca Limited Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
WO2010019796A1 (en) * 2008-08-14 2010-02-18 Chemietek, Llc Heterocyclic amide derivatives as ep4 receptor antagonists
EP2172447A1 (en) * 2007-07-03 2010-04-07 Astellas Pharma Inc. Amide compound
EP2277858A1 (en) * 2008-05-14 2011-01-26 Astellas Pharma Inc. Amide compound

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2001032632A2 (en) 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
EP1787991B2 (en) 2004-07-28 2020-06-24 Takeda Pharmaceutical Company Limited PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE
JP5111113B2 (ja) 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
TW200838526A (en) * 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
US8653091B2 (en) * 2007-04-02 2014-02-18 Evotec Ag Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
US8809538B2 (en) 2009-01-12 2014-08-19 Array Biopharma Inc. Piperidine-containing compounds and use thereof
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
LT2619182T (lt) 2010-09-21 2017-01-25 Eisai R&D Management Co., Ltd. Farmacinė kompozicija
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2016088903A1 (en) 2014-12-05 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0752421A1 (en) * 1995-07-07 1997-01-08 Zeneca Limited Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
EP2172447A1 (en) * 2007-07-03 2010-04-07 Astellas Pharma Inc. Amide compound
EP2277858A1 (en) * 2008-05-14 2011-01-26 Astellas Pharma Inc. Amide compound
WO2010019796A1 (en) * 2008-08-14 2010-02-18 Chemietek, Llc Heterocyclic amide derivatives as ep4 receptor antagonists

Also Published As

Publication number Publication date
DK3325490T3 (da) 2020-02-03
US20180215754A1 (en) 2018-08-02
US10745397B2 (en) 2020-08-18
JP2018527295A (ja) 2018-09-20
US20200339577A1 (en) 2020-10-29
EP3325490A1 (en) 2018-05-30
EP3325490B1 (en) 2019-12-18
CN108368127A (zh) 2018-08-03
CA2993312A1 (en) 2017-01-26
WO2017014323A1 (en) 2017-01-26
JP6689297B2 (ja) 2020-04-28

Similar Documents

Publication Publication Date Title
CN108368127B (zh) 化合物及其作为ep4受体拮抗剂的用途
US11851449B2 (en) Heterocyclic amide compounds having an RORvt inhibitory action
CN105899505B (zh) 用于治疗自身免疫病症的吡唑
JP6556146B2 (ja) 複素環化合物
WO2016021742A1 (en) Heterocyclic compounds as ep4 receptor antagonists
WO2016199943A1 (en) Heterocyclic compounds
CN108026088A (zh) 用作hdac抑制剂的噁二唑衍生物
KR20170016987A (ko) 헤테로시클릭 화합물 및 이들의 레티노이드-관련 희귀 수용체 (ｒｏｒ) 감마-ｔ 저해제로서의 용도
JP6280912B2 (ja) 複素環化合物
JP2019196309A (ja) 複素環化合物
JPWO2017033946A1 (ja) 複素環化合物
WO2011021678A1 (ja) 縮合複素環化合物
JPWO2016039408A1 (ja) 複素環化合物
JPWO2015146929A1 (ja) 複素環化合物
WO2016088903A1 (en) Heterocyclic compounds
WO2014181813A1 (ja) 複素環化合物
WO2015146928A1 (ja) 複素環化合物

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20201211